(3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide
• 英文别名: (3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide
• 化学式: C₁₉H₂₁N₃O₃S
• 分子量: 371.5
• InChiKey: LOGJQOUIVKBFGH-YBEGLDIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Method of treating cancers with SAHA and pemetrexed
  申请人：Pluda James

  公开号：US20070117815A1

  公开（公告）日：2007-05-24

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

  本发明涉及一种治疗需要的受试者癌症的方法，通过向需要的受试者施用一定量的组蛋白去乙酰化酶（HDAC）抑制剂或其药用可接受的盐或水合物的第一量，以及一定量的抗癌药物。HDAC抑制剂和抗癌药物可以被施用以包含治疗有效量。在各种方面，HDAC抑制剂和抗癌药物的效果可能是相加的或协同的。
• METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT
  申请人：KAWAI Masaaki

  公开号：US20110318768A1

  公开（公告）日：2011-12-29

  The present invention provides a method for determining sensitivity of the tumor cells to an EGFR and/or HER 2 inhibitor by evaluating inhibitory capacity of an Src inhibitor in a sample for measuring tyrosine kinase activity which is prepared from a biological sample containing tumor cells, a computer program and a method for determining effectiveness.

  本发明提供了一种方法，通过评估样本中Src抑制剂的抑制能力，测量来自含有肿瘤细胞的生物样本的酪氨酸激酶活性，以确定肿瘤细胞对EGFR和/或HER2抑制剂的敏感性，以及一种用于确定有效性的计算机程序和方法。
• Gastric retentive tablet compositions
  申请人：Wong David

  公开号：US20150110871A1

  公开（公告）日：2015-04-23

  The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.

  本发明涉及一种胃滞留片剂组合物，包括：(1)覆盖颗粒，基本由药物和氨基甲基丙烯酸酯共聚物组成，(2)甲基丙烯酸共聚物和(3)赋形剂，其中1、2和3混合在一起，然后压缩成为胃滞留片剂。因此，覆盖颗粒(项目1)、甲基丙烯酸共聚物和赋形剂均匀分布在片剂中。赋形剂选自缓释剂、粘合剂、填充剂、螯合剂、稀释剂、崩解剂、润滑剂、着色剂、溶解剂或其混合物的组合。覆盖颗粒(项目1)不含甲基丙烯酸聚合物。
• Compositions and Methods for Treatment of Neurodegenerative Disease
  申请人：Zack Donald J.

  公开号：US20130217679A1

  公开（公告）日：2013-08-22

  Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

  本发明揭示了用于治疗与神经退行性疾病或眼部疾病有关的病症的化合物、组合物、试剂盒和方法。
• Biomarker combinations for colorectal cancer
  申请人：Diagnoplex

  公开号：EP2544006A1

  公开（公告）日：2013-01-09

  The present invention relates to methods and kits for the detection of predetermined biomarker BIRC4BP for early diagnosis and management of colorectal cancer.

  本发明涉及用于早期诊断和管理结直肠癌的预定生物标志物 BIRC4BP 的检测方法和试剂盒。